Early combination versus initial metformin monotherapy in the management of newly diagnosed type 2 diabetes: An East Asian perspective

Linong Ji, Juliana C.N. Chan, Miao Yu, Kun Ho Yoon, Sin Gon Kim, Sung Hee Choi, Chien Ning Huang, Shih Te Tu, Chih Yuan Wang, Päivi Maria Paldánius, Wayne H.H. Sheu

Research output: Contribution to journalReview articlepeer-review

Abstract

Type 2 diabetes (T2D) in the East Asian population is characterized by phenotypes such as low body mass index, an index of β-cell dysfunction, and higher percentage of body fat, an index of insulin resistance. These phenotypes/pathologies may predispose people to early onset of diabetes with increased risk of stroke and renal disease. Less than 50% of patients with T2D in East Asia achieve glycaemic targets recommended by national or regional guidelines, which may be attributable to knowledge and/or implementation gaps. Herein, we review the latest evidence with special reference to East Asian patients with T2D and present arguments for the need to use early combination therapy to intensify glycaemic control. This strategy is supported by the 5-year worldwide VERIFY study, which reported better glycaemic durability in newly diagnosed patients with T2D with a mean HbA1c of 6.9% treated with early combination therapy of vildagliptin plus metformin versus those treated with initial metformin monotherapy followed by addition of vildagliptin only with worsening glycaemic control. This paradigm shift of early intensified treatment is now recommended by the American Diabetes Association and the European Association for the Study of Diabetes. In order to translate these evidence to practice, increased awareness and strengthening of the healthcare system are needed to diagnose and manage patients with T2D early for combination therapy.

Original languageEnglish
Pages (from-to)3-17
Number of pages15
JournalDiabetes, Obesity and Metabolism
Volume23
Issue number1
DOIs
StatePublished - Jan 2021

Keywords

  • antidiabetic drug, β-cell function, metformin, type 2 diabetes, vildagliptin

Fingerprint Dive into the research topics of 'Early combination versus initial metformin monotherapy in the management of newly diagnosed type 2 diabetes: An East Asian perspective'. Together they form a unique fingerprint.

Cite this